Literature DB >> 25110824

Extended treatment with brentuximab vedotin in patients with relapsed or refractory CD30-positive hematological malignancies.

Andres Forero-Torres1, Nancy L Bartlett, Robert B Berryman, Robert Chen, Jeffrey V Matous, Michelle A Fanale, Owen A O'Connor, Randal Olshefski, Scott E Smith, Dirk Huebner, Pamela L Levine, Laurie E Grove, Ajay K Gopal.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25110824     DOI： 10.3109/10428194.2014.951843

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  3 in total

1.  Brentuximab vedotin: axonal microtubule's Apollyon.

Authors:  S Mariotto; S Ferrari; M Sorio; F Benedetti; G Tridente; T Cavallaro; A Gajofatto; S Monaco
Journal:  Blood Cancer J       Date:  2015-08-28       Impact factor: 11.037

2.  Hodgkin Lymphoma on Hemodialysis Successfully Treated with Extended Courses of Brentuximab Vedotin.

Authors:  Ayana Uchimura; Hajime Yasuda; Jun Ando; Yasunori Ota; Makoto Sasaki; Tomoiku Takaku; Yutaka Tsukune; Miyuki Tsutsui; Yoko Edahiro; Naoki Watanabe; Tomonori Ochiai; Norio Komatsu; Miki Ando
Journal:  Case Rep Oncol       Date:  2022-03-15

3.  Near Complete Response in a Patient with Classical Hodgkin Lymphoma Treated with Brentuximab Vedotin Concurrent with Radiation Therapy.

Authors:  Wilbur Montana; Dennis Andrew Buck; Tristan Smith
Journal:  Case Rep Oncol       Date:  2017-09-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.